Qihua D. Zhu

639 Longmian Avenue
Nanjing, 211198, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 74 publications

Design, synthesis, and biological evaluation of novel brain-penetrant PARP7 inhibitors for the treatment of ischemic stroke.

Design, synthesis, and biological evaluation of novel brain-penetrant PARP7 inhibitors for the treatment of ischemic stroke.

Journal: European journal of medicinal chemistry

Published: May 21, 2026

Discovery of Highly Potent Phthalazinone Derivatives as PARP14 Inhibitors: From Structure-Based Virtual Screening to In Vivo Pharmacodynamic Activity.

Discovery of Highly Potent Phthalazinone Derivatives as PARP14 Inhibitors: From Structure-Based Virtual Screening to In Vivo Pharmacodynamic Activity.

Journal: Journal of medicinal chemistry

Published: April 20, 2026

Identification of an Orally Bioavailable Quinoline-Based Small-Molecule Tumor Necrosis Factor α (TNF-α) Inhibitor Featuring a Spirocyclic Scaffold.

Identification of an Orally Bioavailable Quinoline-Based Small-Molecule Tumor Necrosis Factor α (TNF-α) Inhibitor Featuring a Spirocyclic Scaffold.

Journal: Journal of medicinal chemistry

Published: March 31, 2026

Discovery of a selective and effective CRBN-recruiting ATR degrader with strong antitumor activity.

Discovery of a selective and effective CRBN-recruiting ATR degrader with strong antitumor activity.

Journal: European journal of medicinal chemistry

Published: March 24, 2026

Correction to "Discovery of Hydroxamic Acid Ester Derivatives as Second-Generation PRMT5 Inhibitors for the Treatment of Triple Negative Breast Cancer".

Correction to "Discovery of Hydroxamic Acid Ester Derivatives as Second-Generation PRMT5 Inhibitors for the Treatment of Triple Negative Breast Cancer".

Journal: Journal of medicinal chemistry

Published: March 07, 2026

Macrophage FOLR2 drives liver fibrosis via intercellular engagement of TGFβRII.

Macrophage FOLR2 drives liver fibrosis via intercellular engagement of TGFβRII.

Journal: Acta pharmacologica Sinica

Published: February 26, 2026

Discovery of Novel and Potent Dual PARP1/ERK Inhibitors as a Promising Strategy for Cancer Therapy.

Discovery of Novel and Potent Dual PARP1/ERK Inhibitors as a Promising Strategy for Cancer Therapy.

Journal: Journal of medicinal chemistry

Published: February 25, 2026

Discovery of Novel Orally Bioavailable Polθ Inhibitors with Arylalkyne Scaffolds for Targeting HR-Deficient Cancers.

Discovery of Novel Orally Bioavailable Polθ Inhibitors with Arylalkyne Scaffolds for Targeting HR-Deficient Cancers.

Journal: Journal of medicinal chemistry

Published: January 29, 2026

Discovery of Oxime Ether Derivatives as Second-Generation PRMT5 Inhibitors for the Treatment of Triple Negative Breast Cancer.

Discovery of Oxime Ether Derivatives as Second-Generation PRMT5 Inhibitors for the Treatment of Triple Negative Breast Cancer.

Journal: Journal of medicinal chemistry

Published: January 13, 2026

Discovery of PKMYT1 Inhibitors with a Novel Scaffold for the Treatment of Triple-Negative Breast Cancer.

Discovery of PKMYT1 Inhibitors with a Novel Scaffold for the Treatment of Triple-Negative Breast Cancer.

Journal: Journal of medicinal chemistry

Published: December 22, 2025

Characterization of Protein-Ligand Chalcogen Bonds: Insights from Database Survey and Quantum Mechanics Calculations.

Characterization of Protein-Ligand Chalcogen Bonds: Insights from Database Survey and Quantum Mechanics Calculations.

Journal: Journal of chemical information and modeling

Published: August 29, 2025

Discovery of a spirocyclic influenza RNA-dependent RNA polymerase inhibitor.

Discovery of a spirocyclic influenza RNA-dependent RNA polymerase inhibitor.

Journal: Bioorganic chemistry

Published: August 14, 2025

Showing 1-12 of 74

Last Updated: 09/26/2026